However, we show here that F1 can be delivered by oral administration to restore memory impairment with reducing Aβ plaque and increasing pCREB and BDNF expression in AD mice, and thus is a more promising candidate to treat AD. This evidence concerns the gene BDNF and Alzheimer disease.